Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19: Newly Authorized Device From OraSure Subsidiary Allows At-Home Collection Of Saliva Samples

Executive Summary

The device is among the first that does not require a health care professional to supervise the saliva sample-collection process.

You may also be interested in...



Pentagon Forks Over Another $109M To Make OraSure’s COVID-19 Antigen Test

The latest funding would upgrade OraSure’s Pennsylvania plant, build a new factory and increase production of its antigen test by 100 million units by 2024.

DOD Contracts OraSure Rapid COVID-19 Tests For $205M

The US defense department’s Defense Logistics Agency will distribute the rapid antigen tests to 25,000 locations around the country to help stymie the spread of SARS-CoV-2 and its variants.

Industry And Investors Ponder Legacy Of Theranos Scandal

What lessons can be learned from the conviction of Theranos founder Elizabeth Holmes, found guilty on four counts of investor fraud in a US court on 4 January?

Topics

Related Companies

UsernamePublicRestriction

Register

MT142946

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel